ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation
Journal for ImmunoTherapy of Cancer · 2026-01 · 14 (1) · e013397
DOI: 10.1136/jitc-2025-013397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 09.01.2026. Verfasst von Hiroki Hayashi und 42 weiteren Autor:innen. Beteiligte Einrichtung: Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan hayashi.hiroki24@chugai-pharm.co.jp. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, CTLA-4 Antigen, Adenosine Triphosphate, Receptors, IgG. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical.
Abstract (Originalsprache)
Background
Intratumoral regulatory T cells (Tregs) are associated with diminished antitumor immunity and poor prognosis in many cancers, with tumor-infiltrating effector Tregs expressing high levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). While Treg depletion is a promising strategy for cancer immunotherapy, systemic Treg depletion may lead to severe autoimmune toxicity. Therefore, to selectively deplete intratumoral Tregs, we used extracellular ATP (exATP), which is highly elevated in solid tumors, as a tumor-selective small molecule.
Methods
We generated ROSE12, a novel anti-CTLA-4 Fc gamma receptors (FcγRs)-binding-enhanced-Fc exATP-dependent switch antibody that reduces Tregs only in the presence of exATP. We evaluated ATP-dependent binding affinity, antibody-dependent cellular cytotoxicity (ADCC) activity in vitro, and antitumor efficacy of monotherapy and combination therapy with anti-programmed death-ligand 1 (PD-L1) in CTLA-4/CD3 double humanized mouse models. Safety profiles were assessed in cynomolgus monkeys.
Results
ROSE12 demonstrated ATP concentration-dependent binding to CTLA-4, with strong binding at 100 µmol/L but no binding without ATP. ROSE12 demonstrated stronger exATP-dependent ADCC activity in vitro and preferentially reduced CTLA-4 + Tregs over activated conventional T cells. The engineered asymmetric re-engineering technology-Fc (ART-Fc) region, a proprietary Fc engineering technology, showed enhanced binding to activating FcγRIIa and FcγRIIIa while reducing binding to inhibitory FcγRIIb. In mouse models, ROSE12 monotherapy significantly inhibited tumor growth in both conventional and PD-L1 therapy-resistant tumors by reducing intratumoral Tregs and increasing CD8 + T-cell infiltration. Combination therapy with anti-PD-L1 showed synergistic antitumor efficacy with enhanced intratumoral CD8 + T-cell activation without increasing systemic immune activation. Unlike FcγRs binding-enhanced conventional anti-CTLA-4, ROSE12 did not induce systemic immune activation or colitis symptoms, demonstrating a 30–300-fold wider therapeutic window. The tumor-selective mechanism was confirmed in humanized mouse models, where ROSE12 reduced only intratumoral Tregs while sparing splenic Tregs. In cynomolgus monkeys, ROSE12 was well tolerated even at 30 mg/kg/week compared with the 3–10 mg/kg/week limits for conventional anti-CTLA-4 antibodies such as non-fucosylated ipilimumab and ipilimumab.
Conclusions
These findings support the clinical development of ROSE12 as a tumor-selective Treg-depleting immunotherapy with potential efficacy in programmed cell death protein-1/PD-L1 therapy-resistant patients. The favorable safety profile was attributed to the ATP-dependent binding mechanism that restricts activity to the high-ATP tumor microenvironment. ROSE12 is currently being evaluated in phase I clinical trials ( NCT05907980 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan hayashi.hiroki24@chugai-pharm.co.jp.
- Chugai Pharmaceutical Co., Ltd., Research Div, Yokohama, Kanagawa, Japan.
- Chugai Pharmaceutical Co., Ltd., Translational Research Div, Yokohama, Kanagawa, Japan.
- Chugai Pharmaceutical Co., Ltd., Translational Research Div, Chuo-ku, Tokyo, Japan.
- Experimental Immunology, Immunology Frontier Research Center; Osaka University, Suita, Osaka, Japan.
Förderung
- Chugai Pharmaceutical
Zitieren
APA
Hayashi, H., Tatsumi, K., Katada, H., Matsuda, Y., Tsunenari, T., Honda, M., Nemoto, T., Shimizu, S., Miura-Okuda, M., Ikuta, Y., Ito, A., Ogami, C., Kato, C., Kamimura, M., Kibayashi, T., Kubo, C., Komatsu, S., Komori, Y., Shinozuka, J., …, & Igawa, T. (2026). ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation. Journal for ImmunoTherapy of Cancer, 14(1), e013397. https://doi.org/10.1136/jitc-2025-013397
Vancouver
Hayashi H, Tatsumi K, Katada H, Matsuda Y, Tsunenari T, Honda M, et al. ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation. Journal for ImmunoTherapy of Cancer. 2026;14(1):e013397. doi:10.1136/jitc-2025-013397
BibTeX
@article{Hayashi2026,
author = {Hayashi, Hiroki and Tatsumi, Kanako and Katada, Hitoshi and Matsuda, Yutaka and Tsunenari, Toshiaki and Honda, Masaki and Nemoto, Takayuki and Shimizu, Shun and Miura-Okuda, Momoko and Ikuta, Yuri and Ito, Ami and Ogami, Chika and Kato, Chie and Kamimura, Masaki and Kibayashi, Tatsuya and Kubo, Chiyomi and Komatsu, Shunichiro and Komori, Yasunori and Shinozuka, Junko and Susumu, Hiroaki and Tanno, Honoka and Tomii, Yasushi and Nakagawa, Kenji and Nagano, Hiroaki and Nanami, Masahiko and Nishito, Yukari and Fujisawa, Nozomi and Matsushita, Tomochika and Michisaka, Saki and Yamazaki, Masaki and Yoshimoto, Moe and Wakatsuki, Hiroaki and Wakabayashi, Tetsuya and Wada, Naoko A and Ueda, Otoya and Konishi, Hiroko and Kashima, Kenji and Tanaka, Hiroshi and Endo, Mika and Kitazawa, Takehisa and Sakaguchi, Shimon and Kamata-Sakurai, Mika and Igawa, Tomoyuki},
title = {ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {1},
pages = {e013397},
doi = {10.1136/jitc-2025-013397}
}
EUVIMED